The company reported disappointing clinical results.
News & Analysis: MATINAS BIOPHARMA
The proposed brand name for its leading pipeline drug got an important nod.
The company announced the pricing of a public stock offering.
The small-cap pharma sank on an update from its top competitor.
Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.
Matinas BioPharma's lead candidate failed to hit the mark in a mid-stage trial.